Zobrazeno 1 - 10
of 20
pro vyhledávání: '"H. L. Pearce"'
Autor:
H. L. Pearce
Publikováno v:
Annals of Oncology. 6:S55-S62
Summary Background The discovery and clinical development of new drugs to treat cancer at Lilly Research Laboratories has undergone significant change during the past 15 years. During the early 1980s drug discovery relied heavily on a panel of syngen
Autor:
H. L. Pearce, J. M. Colacino, Chou Ta-Sen, C. D. Jones, T. E. Mabry, G. B. Grindey, J. F. Worzalla
Publikováno v:
Nucleosides and Nucleotides. 13:1125-1133
The synthesis of β-dFARPP was accomplished by Mitsunobu coupling of 6-cyanopurine with 2-deoxy-2, 2-difluororibose followed by purine ring-expansion under the action of methanolic ammonia. The title compound inhibited the growth of proliferating hum
Autor:
J. M. Colacino, H. L. Pearce, Chou Ta-Sen, Gerald B. Grindey, Chauncey D. Jones, John F. Worzalla, T. E. Mabry
Publikováno v:
ChemInform. 26
Autor:
N, Suh, A L, Glasebrook, A D, Palkowitz, H U, Bryant, L L, Burris, J J, Starling, H L, Pearce, C, Williams, C, Peer, Y, Wang, M B, Sporn
Publikováno v:
Cancer research. 61(23)
Arzoxifene ([6-hydroxy-3-[4-[2-(1-piperidinyl)-ethoxy]phenoxy]-2-(4-methoxyphenyl)]benzo[b]thiophene) is a selective estrogen receptor modulator (SERM) that is a potent estrogen antagonist in mammary and uterine tissue while acting as an estrogen ago
Publikováno v:
Seminars in oncology. 24(2 Suppl 7)
Gemcitabine (2',2'-difluorodeoxycytidine) is a novel nucleoside analogue that exerts its antitumor activity via multiple mechanisms of action. These include (1) incorporation of gemcitabine into replicating DNA, which inhibits DNA replication and cel
Publikováno v:
Molecular pharmacology. 48(4)
We previously showed that there is a structure-function relationship among reserpine and yohimbine analogues in their ability to inhibit the function of P-glycoprotein (P-gp) and reverse multidrug resistance (MDR). Because some P-gp inhibitors (e.g.,
Publikováno v:
Acta Crystallographica Section B Structural Crystallography and Crystal Chemistry. 30:2360-2363
Publikováno v:
Journal of the American Chemical Society. 97:542-554
Publikováno v:
Acta Crystallographica Section B Structural Crystallography and Crystal Chemistry. 32:296-298
Publikováno v:
Cancer research. 49(13)
The systemic use of thiol-containing uroepithelial protecting agents, e.g., N-acetylcysteine (NAC) or mesna, in conjunction with the alkylating agent cyclophosphamide is predicated on the assumption that the toxic metabolic by-products will be consum